AUPH

Voclosporin

Lupus Nephritis

Stage (next event)

Expected Date

PDUFA

Jan 22, 2021

Catalyst Info & Data Links

TITLE: Voclosporin for Lupus Nephritis - PDUFA

  • ClinicalTrial.gov (NCT03597464): Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin (AURORA2)


WHAT IS THE NEXT CATALYST EVENT?

  •  PDUFA


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA


PRESS RELEASES

 POSTERS

  • TBA


PRESENTATIONS


PUBLICATIONS



MECHANISM OF ACTION/RATIONALE

  • Vaclosporin is a structural analog of cyclosporine A 

  • Immunosuppressant with a synergistic and dual mechanism of action 

  • It binds to calcineurin through the latch region which blocks IL-2 expression and T-cell mediated immune responses and stabilized podocytes in the kidney

  • Click here to learn more

COMPETITORS

  • RC18 (Telitacicept) - RemeGen

  • Abatacept (Orencia) - Bristol-Myers Squibb

  • Anifrolumab - AstraZeneca/MedImmune

  • Blisibimod - Anthera/Amgen

  • Lupuzor - ImmuPharma

MARKET

  • ~63,000 patients with LN in U.S. (source)

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon